Lucinda Steward Phd Email & Phone Number

Belgium

Braine-L’Alleud Braine-L’Alleud, Wallonia, Belgium

Neuroscience, in vitro pharmacology: Leading a team of 6 scientists in the molecular neuroscience, studying the pharmacological profile of targets, establishing target/ligand engagement and interaction assays to monitor cellular effects. Leading programs. Membership of the Neuroscience Leadership Team

Basel Area, Switzerland

Preclinical matrix project team leader• Led up to 10 functional experts, target assessment, lead generation, lead optimization to entry into human, preparation for phase I/II trials. • Responsible for strategy implementation, driving the project forward with scientific leadership, championing the target, meeting clinical and target product profiles.• Communicated and presented project progress and strategy for key milestones to management and scientific advisory boards Expert in neuroscience• Neurodevelopmental (autism) and Psychiatric disorders (e.g. Schizophrenia) and Rare Diseases (TSC, Huntington Disease (HD)) • Led neuropharmacology laboratory utilizing neural stem cell and tissue based assays; Extensive knowledge of cellular signalling , GPCR and LGIC receptors and mTORC pathway.• Leading transgenic animal breeding. Study director for in vivo and ex vivo tissue studies for the HD and Alzheimer Disease programs. • Preclinical representative on HD anti-HTT ASO clinical team• New target proposals and project initiation• Evaluating partnering opportunities and performing due diligence assessments• Writing patents, investigator brochures and regulatory documentsLine management• Up to 5 associates; setting tasks, priorities and goals, performance assessment, supporting and mentoring development, encouraging teamwork• Initiating and maintaining collaborations with companies and academic institutions Additional Experience• Medical Affairs Scientific Communications Neuroscience (2018; rotation 6 months) Narrative document (HD HTT-ASO, ALS programs, Q&A for MSLs, white paper, conference presentations and communication strategy• External drug discovery (EDD) 2014 - 15 (1 year, 10%). Assessing external alliances and venture partners • General Project Management 2013 (4 months, 50%), development team; coordination project activities early development Ph I to II, team communication; meeting facilitation, project presentations

Slough, United Kingdom

• Immunological projects to treat autoimmune diseases• Used recombinant and native chemokine GPCR’s (human blood and T-cell lines), Ca2+ imaging, [35S]GTPγS, chemotaxis, in situ hybridisation, FACS, MACs cell type selection• Supervision post-doctoral scientist and student

• Assessing atypical antipsychotic mode of action, using animal models of schizophrenia (sub-chronic PCP dosing) acute and chronic antipsychotic treatment (implantation of osmotic mini-pumps, s.c. and i.p. administration)• Used autoradiography, dual labeling immuno-histochemistry and in situ hybridisation for protein and mRNA determination measuring 5-HT and muscarinic receptor plasticity, immediate early gene induction, GABAergic marker change

Edmonton, Canada

• Identifying 5-HT3 receptor ligand recognition site using site directed mutagenesis• Canadian MRC personal fellowship selected for special funding by Pfizer Canada

Birmingham, United Kingdom

• 5-HT3, 5-HT4 and AT receptor distribution and pharmacology using radioligand binding (homogenate, autoradiography), dopamine release (in vitro and in vivo microdialysis)

Doctor Of Philosophy (Ph.D.), Neuropharmacology

PhD thesis Neuropharmacology of 5-HT3 and 5-HT4 receptors

Bachelor’S Degree, Applied Biological Sciences, Hons 2:1

Activities and Societies: Field Hockey Captain 1st XIFour year degree 1st Year: Biochem, microbiology, physiology, mol.biol., statistics.

Leadership & Teamwork Course

Team Leadership